---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-073875"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T17:33:25.543739+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Eloxx holders elect all 5 director nominees, ratify auditor, approve say-on-pay

## Summary
- All five director nominees elected: Kariv (557,994 for), Aggarwal (511,136), Androski (559,991), Rubin (509,103), Walts (559,951).
- Ratification of Baker Tilly as auditor passed with 1,181,736 for, 23,057 against, 48,182 abstain.
- Advisory say-on-pay vote approved: 550,254 for, 12,373 against, 42,508 abstain; 647,840 broker non-votes.
- Approximately 57.83% of outstanding shares were represented at the meeting.

## SEC filing metadata
- accession: 0001104659-23-073875
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923073875/0001104659-23-073875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923073875/tm2319166d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-073875
- JSON: https://secwatch.observer/filing/0001104659-23-073875.json
- Plain text: https://secwatch.observer/filing/0001104659-23-073875.txt

## Key facts
- Shareholder Votes
  Eloxx Pharmaceuticals, Inc. shareholders approved Election of five directors to hold office until the 2024 annual meeting at the 2023-06-22 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal 1 - Election of five (5) directors to hold office until the Company’s annual meeting of stockholders to be held in 2024 and until his or her respective successor is duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465923073875/0001104659-23-073875-index.htm
- Shareholder Votes
  Eloxx Pharmaceuticals, Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2023-06-22 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal 3 - Advisory vote on the compensation of the Company’s named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465923073875/0001104659-23-073875-index.htm
- Shareholder Votes
  Eloxx Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-22 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal 2 - Ratification of the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465923073875/0001104659-23-073875-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.